Arcellx/$ACLX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Arcellx

Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.

Ticker

$ACLX
Primary listing

Industry

Biotechnology

Employees

163

ISIN

US03940C1009

Arcellx Metrics

BasicAdvanced
$3.8B
-
-$3.00
0.34
-

Bulls say / Bears say

Arcellx's Phase 2 iMMagine-1 study demonstrated a 97% overall response rate and 62% complete response rate in patients with relapsed or refractory multiple myeloma, indicating strong clinical efficacy. (stocktitan.net)
The company reported $676.7 million in cash and equivalents as of Q3 2024, expected to fund operations into 2027, providing a solid financial foundation for ongoing research and development. (stocktitan.net)
Arcellx's collaboration with Gilead's Kite division, including a $200 million equity investment at a 30% premium, underscores strong industry confidence in its technology and potential. (financecharts.com)
In Q1 2025, Arcellx reported a loss of $1.13 per share, missing the consensus estimate of a $0.84 loss, indicating financial underperformance. (nasdaq.com)
The company's Q1 2025 revenue of $8.13 million fell short of the expected $18.19 million, reflecting challenges in meeting revenue projections. (nasdaq.com)
Insider selling activity, including the sale of 38,300 shares by insider Rami Elghandour, may raise concerns about internal confidence in the company's future performance. (defenseworld.net)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ACLX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs